Great poster presentations and reception at the #2024PSMAConference! Congratulations to our awardees - Reinier Hernandez, @josef_zahner, and @Wes_Armstrong_ !
New study led by UCLA & UCSF finds PSMA PET, a molecular imaging tool, can provide prognostic information before treatment begins that can predict if the patient will have a high risk for prostate cancer returning after surgery.
https://t.co/E5iKCPlDY7
Follow-up of the surgical cohort of the Pivotal Trial used for the FDA approval of 68Ga-PSMA-11 PET in @EUplatinum: Pre-surgical PSMA-PET is a strong prognostic biomarker improving pre-operative BCR-FS risk assessment.
https://t.co/c2Zw9n97Zm
https://t.co/HjyxxGY5Qt
The #UCLA Nuclear Medicine Clinical Research Team presented 7 abstracts on PSMA-PET/CT at #ASCO23. Little by little, we try to learn and share how to interpret and use the PSMA-PET information for Optimizing Treatment Decision-Making.
https://t.co/ItLoF1hXij
PSMA PET guided salvage radiotherapy among patients with #ProstateCancer in the post-prostatectomy setting: a single center posthoc analysis. Presented by @CalaisJeremie@UCLAJCCC. #ASCO23 written coverage by @RKSayyid@UofT > https://t.co/7YO0wE840o @ASCO
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. Presented by @DjailebLoic@UCLATheranostic > https://t.co/lAro7c1iWX @zklaassen_md#ASCO23
PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp. #ASCO23 written coverage by @zklaassen_md@GACancerCenter > https://t.co/39xOmo58zi @ASCO